RNA-based testing improves detection of MET exon 14 skipping in NSCLC, identifying mutations missed by DNA-only assays, according to new research. Findings may impact eligibility for targeted therapies.
Revvity is developing the T-SPOT A201, an automated platform for latent tuberculosis testing in high-volume labs, with planned launch in 2027 pending regulatory approval.
A new NIH-funded study finds that elevated circular RNAs in blood may predict Alzheimer’s symptoms years in advance, outperforming current blood tests in forecasting disease progression.
The assay is designed to detect minimal residual disease with greater sensitivity than conventional flow cytometry.
The assay from Seegene USA simultaneously detects and differentiates herpes simplex virus, varicella-zoster virus, and monkeypox virus.
Researchers identified coordinated lipid, metabolite, and protein signatures in symptomatic patients, supporting a multi-omic strategy for earlier ovarian cancer detection.
A new ultrasensitive blood test may detect Sjögren’s disease more than 10 years before symptoms appear by identifying chronically elevated interferon alpha levels in patient blood samples.
The assay measures lipoprotein(a) levels in molar units to improve cardiovascular risk assessment and standardization across laboratories.
NanoSomiX and Beckman Coulter Diagnostics have partnered to develop automated blood-based immunoassays for detecting neurodegenerative disease biomarkers, aiming to enable scalable testing in clinical and research laboratories.
Researchers from Charité – Universitätsmedizin Berlin report that steatotic liver disease subtypes often shift over time, with 36% of MetALD patients reclassified within six months, suggesting a need for dynamic disease monitoring.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.